Nanomaterials for Parkinson disease: Recent progress

Abstract Even though Parkinson's disease (PD) is the second most common neurological disorder (ND), it faces an absence of credible drug delivery, treatment and diagnosis. Levodopa is the best drug of choice among the current conventional products designed as anti-Parkinson drugs, but its poor brain transfer and low bio-availability is a most challenging problem for levodopa. To address these drawbacks, drug delivery nanoparticles (NP) acted as an outstanding tool for optimizing the medicinal effectiveness of anti-Parkinson drugs. NPs enabled the drug to be administered via various routes to eliminate the demand to pass blood–brain barrier (BBB). Also diagnosis of PD in early stage is another wing of efficient management of this disease. There are several barriers to traditional diagnosis of Disease. Nanotechnology could provide insightful solutions to this problem. The current study examines the recent innovations in the improvement of nanotechnology diagnosis and treatment platforms for PD. A number of nanoparticles (carbon nanotubes, silver, gold, graphene, etc.) along with different approaches to biosensing and treatment are discussed here which have the potential to be used in PD.